Ann: Final Antibody Selection Complete, page-32

Couple of quotes from an article about VolitionRX- do not advertise external links/companies/news/207876/volitionrx-s-revolutionary-nuq-blood-tests-could-change-the-future-of-cancer-screening-207876.html

The kits cost $500 to $1,000, but if the buyer discovers something interesting in the blood assays, they must return to Volition for product licenses, another potential revenue generator. 

The first Nu.Q tests to detect colorectal cancer are likely to hit Europe by the end of next year, followed by Asia in 2020 and the US by 2021. But Reynolds says the company won’t see “serious” revenue until 2021 or 2022.

So they’re looking at having a product to market in Europe by late 2019. The kits seem expensive compared to Colostat. Be interesting to compare performance. Volition is cashed up with lots of resources. It sounds like the race is on! Bear in mind their shares are $2.57 USD and they have a $90M mkt cap...